Table 1.

Characteristics of the Cohort

	Entire Cohort (N=441)	SSI (N=66)	No SSI (N=375)	p-value
Age, in years	53 (±13.1)	52.2 (±11.1)	53.2 (±13.5)	0.55
Sex, men	257 (58%)	39 (59%)	218 (58%)	0.88
Race, African American	225 (52%)	37 (57%)	188 (51%)	0.36
Body Mass Index (BMI), mean (SD)	29.7 (±6.0)	31.7 (±5.7)	29.4 (±5.9)	0.004
BMI < 25	117 (27%)	13 (20%)	104 (28%)	--
BMI ≥ 25 and < 30	130 (30%)	14 (21%)	116 (30%)	0.93
BMI ≥ 30	184 (42%)	37 (56%)	147 (39%)	0.01
Chronic disease score, mean (SD)	10.8 (±3.5)	11.4 (±3.6)	10.7 (±3.5)	0.19
Charlson score, mean (SD)	3.3 (±1.6)	3.4 (±1.8)	3.3 (±1.5)	0.64
Donor type, cadaveric	315 (71%)	46 (69%)	269 (72%)	0.74
Repeat transplant	56 (13%)	6 (9%)	50 (13%)	0.34
Ischemia time, in minutes	1127.5 (869)	1184.3 (927.3)	1116.3 (858.1)	0.57
NHSN risk index
= 1	35 (7.9%)	5 (8%)	30 (8%)
= 2	316 (73%)	43 (73%)	268 (72%)
= 3	90 (20%)	13 (20%)	77 (21%)
Surgical Prophylaxis*	433 (98%)	64 (97%)	369 (98%)	0.42
Induction Immunesuppression
Thymoglobulin	70 (16%)	12 (18%)	58 (15%)	0.58
Alemtuzemab^	224 (51%)	37 (56%)	187 (50%)	0.35
Basiliximab^	144 (33%)	17 (26%)	127 (34%)	0.20
Procedure duration, in minutes	197.4 (±71.3)	192.9 (±62.7)	198.2 (±72.8)	0.58
Estimated blood loss, in ml	408 (±395)	413 (±377)	408 (±398)	0.93
Hospital length of stay, Median (interquartile range)	6.2 (5.1 to 8.5)	6.7 (5.3 to 9.9)	6.0 (5.0 to 8.4)
Second operation during index hospitalization	61 (14%)	15 (23%)	46 (12%0	0.02
Readmission at 30 days	50% (220)	94% (62)	42% (158)	<0.01
Death at 30 days	1 (0.2%)	0	1 (0.3%)	--

SSI – Surgical Site Infection

^*Surgical prophylaxis – documentation of receipt of appropriate antibiotics (as defined by University of Maryland Medical Center protocol) within 1 hour of surgical incision

^{^}2 patients received both alemtuzemab and basiliximab as induction immunesuppression